SOCIAL IMPACT
IMPACTING THE FUTURE OF MEDICINE THROUGH FINANCING NEW THERAPEUTIC PLATFORMS
Advanced biotherapeutics are key to addressing the challenges of modern-day healthcare with spiralling costs of long-term chronic illness and lack of cures
RESPONSIBLE INVESTMENTS INTO GOOD HEALTH AND WELL-BEING
4BIO Capital is a signatory of the UN Principles for Responsible Investment, and actively implements ESG criteria in its investment practices.
In 2015, the UN adopted the Agenda for Sustainable Development, including a set of 17 Sustainable Development Goals (SDGs), of which GOOD HEALTH AND WELL-BEING IS RANKED #3
-
Uncurbable, often fatal genetic diseases in adults and children
-
Large cost on society and individuals through disability and childhood mortality
-
Most of the morbidity, quality of life pressures and healthcare spending arise from non-communicable diseases that are mainly degenerative in nature
-
Existing therapeutic platforms do not address the issue adequately and are often symptomatic
-
Save lives treating genetic disorders early in life
-
May solve disabling diseases including cardiovascular, oncological and neurodegenerative disorders
-
Biotherapeutics supplement or facilitate natural functions of the organism
-
Manufacturing is biological in nature and decreases the dependence on fossil fuels
ADA-SCID (BUBBLE BOY DISEASE)
EXAMPLE OF 4BIO CAPITAL HIGH SOCIAL IMPACT INVESTMENTS
-
Defect of the ADA gene resulting in a deficiency in ADA enzyme levels
-
Severe combined immunodeficiency
-
Recurrent infections leading to death in the first year of life if untreated
CURRENT TREATMENT OPTIONS:
-
Survival is still the key
-
Chronic enzyme replacement therapy with pegylated ADA
-
We invested into the best-in-class, curative therapy for the disease
